Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event.


Journal

International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 10 04 2019
accepted: 14 08 2019
pubmed: 23 8 2019
medline: 16 12 2020
entrez: 22 8 2019
Statut: ppublish

Résumé

Multiple sclerosis (MS) patients whose first demyelinating event is optic neuritis have been claimed to display a milder disease course and reduced physical disability. Our aim was to investigate the impact of the clinical features of the first clinical episode on cognitive disability and sleep dysfunction in MS. A total of 26 (10 with optic neuritis as the first clinical event) MS patients were recruited. A comprehensive sleep study was performed, and a panel of tests were administered to examine cognitive and motor performance. Serum levels of sleep-related mediators orexin-A and melatonin were measured by enzyme-linked immunosorbent assay. Subjective sleep quality was evaluated by Pittsburgh sleep quality test, and daytime excessive sleepiness was tested by Epworth sleepiness scale. MS patients with the first clinical episode of optic neuritis and patients with at least one optic neuritis attack exhibited increased daytime sleepiness, higher sleep efficiency and NREM duration and lower total wake time. Patients with a history of optic neuritis obtained more favorable scores in neuropsychological tests measuring executive functions and complex attention as compared to those who had never experienced optic neuritis. Melatonin and orexin-A levels were lower in patients with optic neuritis onset. The higher no. of optic neuritis attacks was associated with reduced wake time and higher symbol digit modalities test scores. Having a history of optic neuritis is associated with improved sleep quality and executive functions but increased daytime sleepiness. Reduction of orexin-A and melatonin levels might be one of the underlying mechanisms.

Identifiants

pubmed: 31432354
doi: 10.1007/s10792-019-01157-x
pii: 10.1007/s10792-019-01157-x
doi:

Substances chimiques

Biomarkers 0
Melatonin JL5DK93RCL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-158

Subventions

Organisme : Istanbul Üniversitesi
ID : 30783

Références

J Neurol. 2004 Jul;251(7):885-6
pubmed: 15258796
J Sleep Res. 2017 Aug;26(4):428-435
pubmed: 28093823
J Clin Sleep Med. 2012 Oct 15;8(5):597-619
pubmed: 23066376
Clin Neuropsychol. 2017 Jan;31(1):179-192
pubmed: 27707354
Sleep. 2016 Aug 01;39(8):1525-33
pubmed: 27166237
Neurol Sci. 2019 May;40(5):1067-1070
pubmed: 30645749
Sleep Med. 2013 Mar;14(3):229-36
pubmed: 23352029
Int J Mol Sci. 2013 Mar 12;14(3):5817-41
pubmed: 23481642
Endocrinology. 2001 Jun;142(6):2677-85
pubmed: 11356719
Neurol Res. 2017 Apr;39(4):323-330
pubmed: 28191860
Neurosci Lett. 2010 Apr 19;474(1):9-12
pubmed: 20193740
Immunol Invest. 2019 Feb;48(2):190-197
pubmed: 30321074
Sleep Med. 2003 Mar;4(2):101-19
pubmed: 14592341
Acta Neurol Scand. 2007 Jan;115(1):1-11
pubmed: 17156260
Sleep. 2004 Jun 15;27(4):619-27
pubmed: 15282996
J Pineal Res. 2018 Nov;65(4):e12525
pubmed: 30242884
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
J Neurol. 2018 Sep;265(9):2071-2078
pubmed: 29974206
Neurology. 1999 Aug 11;53(3):473-8
pubmed: 10449106
Psychoneuroendocrinology. 2002 May;27(4):505-17
pubmed: 11912002
Epilepsy Behav. 2019 Mar;92:176-183
pubmed: 30665125
Mult Scler. 2001 Feb;7(1):59-65
pubmed: 11321195
Clin Interv Aging. 2015 May 06;10:839-46
pubmed: 26005338
Curr Treat Options Neurol. 2019 Jan 31;21(1):4
pubmed: 30701337

Auteurs

Recai Türkoğlu (R)

Department of Neurology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.

Gülçin Benbir (G)

Department of Neurology, Cerrahpaşa Faculty of Medicine, İstanbul University Cerrahpaşa, Istanbul, Turkey.

Selen Özyurt (S)

Department of Neurology, Cerrahpaşa Faculty of Medicine, İstanbul University Cerrahpaşa, Istanbul, Turkey.

Erdil Arsoy (E)

Department of Neurology, Cerrahpaşa Faculty of Medicine, İstanbul University Cerrahpaşa, Istanbul, Turkey.

Ece Akbayır (E)

Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Selin Turan (S)

Department of Neurology, Cerrahpaşa Faculty of Medicine, İstanbul University Cerrahpaşa, Istanbul, Turkey.

Derya Karadeniz (D)

Department of Neurology, Cerrahpaşa Faculty of Medicine, İstanbul University Cerrahpaşa, Istanbul, Turkey.

Vuslat Yılmaz (V)

Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Mehmet Gencer (M)

Department of Neurology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey.

Erdem Tüzün (E)

Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. drerdem@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH